IFNG and plasma cell myeloma: Neutralization of TNF-α, but not IFN-γ, significantly inhibited myeloma cell killing (Fig. 4c) and NK cell activation (Fig. 4d, e) in elotuzumab, as well as elotuzumab plus lenalidomide co-cultures.